New study aims to spot hidden danger in diabetes drug overdoses

NCT ID NCT07193069

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier de Saint-Denis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines patients in intensive care who have overdosed on metformin, a common diabetes drug. Researchers will compare those who took only metformin with those who also took dapagliflozin, another diabetes medication. The goal is to find specific signs that could help doctors quickly recognize a dapagliflozin overdose and improve treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin
What this could lead to: If successful, this study could help doctors quickly identify a dapagliflozin overdose in patients with metformin poisoning, leading to better care in the ICU.
What could go wrong: This is a small observational study with only 50 participants, so results may not apply to all patients. It is not testing a new treatment, only looking for patterns.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DAPAGLIFLOZIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic ketoacidosis Drug Overdose lactic acidosis poisoning

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DAPAGLIFLOZIN DIABETIC KETOACIDOSIS DRUG OVERDOSE INTENSIVE CARE UNITS LACTIC ACIDOSIS METFORMIN

Contacts and locations

Show contact details

Locations

Centre Hospitalier de Saint-Denis
RECRUITING

Saint-Denis, France, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.